KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 113 filers reported holding KALVISTA PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 1.54 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $28,453,000 | +11.4% | 1,930,322 | 0.0% | 0.62% | +38.0% |
Q4 2021 | $25,538,000 | -24.2% | 1,930,322 | 0.0% | 0.45% | -3.6% |
Q3 2021 | $33,684,000 | -27.2% | 1,930,322 | 0.0% | 0.47% | -37.1% |
Q2 2021 | $46,251,000 | +414.4% | 1,930,322 | +451.5% | 0.74% | +445.6% |
Q1 2021 | $8,992,000 | -78.2% | 350,000 | -75.7% | 0.14% | -92.4% |
Q1 2019 | $41,243,000 | +44.9% | 1,441,070 | 0.0% | 1.78% | +7.3% |
Q4 2018 | $28,461,000 | -10.7% | 1,441,070 | 0.0% | 1.66% | -2.7% |
Q3 2018 | $31,862,000 | +172.3% | 1,441,070 | 0.0% | 1.70% | +124.1% |
Q2 2018 | $11,701,000 | -14.3% | 1,441,070 | 0.0% | 0.76% | -27.4% |
Q1 2018 | $13,661,000 | -2.8% | 1,441,070 | 0.0% | 1.05% | -11.0% |
Q4 2017 | $14,050,000 | +223.0% | 1,441,070 | +143.8% | 1.18% | +199.2% |
Q3 2017 | $4,350,000 | 0.0% | 591,070 | 0.0% | 0.39% | -21.2% |
Q2 2017 | $4,350,000 | -5.8% | 591,070 | 0.0% | 0.50% | -11.8% |
Q1 2017 | $4,616,000 | +10.5% | 591,070 | 0.0% | 0.57% | -4.4% |
Q4 2016 | $4,179,000 | – | 591,070 | – | 0.59% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 1,551,719 | $22,515,000 | 5.42% |
Prosight Management, LP | 530,062 | $7,691,000 | 4.12% |
TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $26,118,000 | 3.20% |
Vivo Capital, LLC | 1,533,559 | $22,252,000 | 2.46% |
Frazier Life Sciences Management, L.P. | 1,572,192 | $22,813,000 | 1.76% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 316,133 | $4,587,000 | 1.47% |
Deep Track Capital, LP | 1,824,000 | $26,466,000 | 1.21% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,707,100 | $24,770,000 | 1.03% |
DAFNA Capital Management LLC | 255,313 | $3,705,000 | 1.00% |
COMMODORE CAPITAL LP | 312,553 | $4,535,000 | 0.73% |